Cerebellar tDCS + Language Therapy for Aphasia
(CeSAR Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new method to help people regain language skills after a stroke. It combines brain stimulation, known as cerebellar tDCS (a gentle electrical treatment), with language therapy to determine if this enhances recovery from aphasia (difficulty with speech and understanding language). Participants will receive either the actual treatment or a placebo, both paired with naming exercises. The trial seeks individuals who have experienced a stroke causing aphasia and naming issues, are fluent in English, and have lived with these conditions for at least six months. As an unphased trial, this study offers participants the chance to contribute to groundbreaking research that could improve recovery options for stroke survivors.
Do I need to stop taking my current medications for the trial?
You may need to stop taking certain medications, especially those that lower the seizure threshold or NMDA antagonists, as they are listed in the exclusion criteria.
What prior data suggests that cerebellar tDCS is safe for post-stroke aphasia therapy?
Research has shown that cerebellar cathodal transcranial direct current stimulation (tDCS) is generally safe for people. In earlier studies, participants who received this treatment often noticed only slight improvements in language or quality of life. Importantly, these studies did not find any serious side effects or negative reactions. This suggests that the treatment is safe, although its effectiveness in improving language can vary.
Since this trial is studying cerebellar tDCS, a method previously tested, the safety profile is likely similar to past studies. Participants can feel reassured that this treatment has been tested and is considered safe for humans.12345Why are researchers excited about this trial?
Researchers are excited about cathodal cerebellar tDCS for aphasia because it offers a new approach to improving language function. Unlike traditional speech therapy alone, this treatment combines non-invasive brain stimulation with Semantic Feature Analysis (SFA) to potentially enhance speech recovery. The treatment specifically targets the right cerebellum with electrical currents to help retrain the brain's language pathways, which could lead to more effective results in a shorter timeframe. This innovative combination could provide new hope for those with aphasia by accelerating and amplifying the benefits of standard speech therapy.
What evidence suggests that cerebellar tDCS is effective for aphasia?
This trial will compare the effects of cathodal cerebellar transcranial direct current stimulation (tDCS) combined with Semantic Feature Analysis (SFA) naming treatment to a sham version of the same treatment. Studies have shown that cathodal cerebellar tDCS, when paired with speech therapy, can help people with post-stroke aphasia improve their language skills. This treatment appears to ease everyday conversations. Some research suggests that while overall language abilities might not change significantly, certain aspects of quality of life could improve. In simple terms, people may find it easier to express themselves in daily life. Early evidence supports the idea that this approach can be a helpful addition to language therapy for aphasia recovery.12467
Who Is on the Research Team?
Rajani Sebastian, PhD
Principal Investigator
Johns Hopkins University
Are You a Good Fit for This Trial?
This trial is for English-speaking adults over 18 who had a stroke in the left hemisphere of their brain at least 6 months ago, resulting in aphasia and difficulty naming things. They must have been right-handed before the stroke. People with cerebellum damage, other neurological or psychiatric disorders, recent seizures, severe sensory loss, certain medication use, high baseline naming test scores, metal in their head or body implants are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 15 sessions of cerebellar tDCS combined with Semantic Feature Analysis (SFA) over 3-5 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Cathodal Cerebellar tDCS
Find a Clinic Near You
Who Is Running the Clinical Trial?
Johns Hopkins University
Lead Sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
Collaborator